2h
Dealbreaker on MSNRecursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH TumultAltitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered ...
Earlier this month, the Trump administration directed the National Institutes of Health (NIH) to impose limits on specific ...
If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the ...
US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of ...
The cuts hit the FDA’s medical device center particularly hard, impacting product reviewers and researchers of AI-enabled ...
The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.
Salt Lake City-based accelerator Altitude Lab is hoping it can entice biotechs impacted by the uncertainty surrounding federal grants.
Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and ...
Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.
It's not yet clear whether the NIH matter will reach USAID-levels of intensity among Democrats and the media. But it's off to a strong start.
NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants involving innovator drugs totalled over $1.4bn between 2020 and 2025 year to date, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results